Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00791323 · ClinicalTrials.gov registry record · Phase 4
Efficacy of Ketorolac 0.4% in Prostaglandin Suppression
A Phase 4 study of Inflammation, sponsored by Allergan.
- Completed
- Registry status
- Phase 4
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT00791323 is a Phase 4 study of Inflammation that has completed, run by Allergan. The registered enrollment target is 9 participants, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00791323, a Phase 4 study of Inflammation, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
A pilot study to evaluate the extent of PGE2 inhibition (mean aqueous values) by Ketorolac 0.04% following peripheral iridotomy
Conditions Studied
Interventions
- DRUG Ketorolac 0.4%
- DRUG Lubricating Eye Drop
Study Locations (1)
Texas
- - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2008-11 |
| Est. Completion | 2009-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00791323
The ClinicalTrials.gov registry entry for NCT00791323 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (97% lower). The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Inflammation appearing as the primary indexed condition, and to 2 interventions - of which Ketorolac 0.4% is the first listed.
NCT00791323 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00791323 about?
NCT00791323 is a clinical study titled "Efficacy of Ketorolac 0.4% in Prostaglandin Suppression". A pilot study to evaluate the extent of PGE2 inhibition (mean aqueous values) by Ketorolac 0.04% following peripheral iridotomy
What is the current status of trial NCT00791323?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 9 participants. The study started on 2008-11. Estimated completion is 2009-08.
What conditions does trial NCT00791323 study?
This clinical trial studies the following conditions: Inflammation.
What interventions are being tested in trial NCT00791323?
The interventions under investigation include: Ketorolac 0.4% (DRUG), Lubricating Eye Drop (DRUG).
Who is sponsoring clinical trial NCT00791323?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00791323 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Skin Barrier Function and Inflammation in Aging: The BIA Study
RECRUITING · Phase 4
-
Systemic Immunomodulatory Effects and Pharmacogenetics of Atorvastatin in Early Atherosclerosis
COMPLETED · Phase 4
-
Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes
COMPLETED · Phase 4
-
Impact of Ascorbic Acid on Post-Cardiothoracic Surgery Inflammation
COMPLETED · Phase 4
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
-
Reducing Suicide Risk Among Aging Caregivers of Persons With AD/ADRD
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.